Ariel Investments, LLC 13F holdings and portfolio analysis

Directly following the baseline exposes an investor to a broad but still cyclical small-blend portfolio with reporting-lag risk. The artifact shows top-5 concentration at 17.88%, top-10 at 32.62%, and sector weights led by Consumer Discretionary at 21.10% and Financials at 21.07%, followed by Health Care at 14.70% and Communication Services at 13.33%. Performance-wise, the baseline earned 7.59% annualized and 102.0% total return, but with -2.62 alpha, -35.30% max drawdown, 3,063 trades, and 1.17% total estimated cost. So the exposure is not single-name extreme, but it is still a lagged, turnover-heavy, cyclical portfolio that did not beat SPY.

The recent baseline periods show why the strategy feels acceptable in some windows but disappointing overall. The best recent relative periods were 2025-03-31, when optimized excess return was +0.12, and 2025-09-30, when excess return reached +1.06. But several nearby periods were materially weaker: 2025-06-30 posted -5.50 excess return, 2024-09-30 posted -4.33, 2023-06-30 posted -6.06, and 2022-12-31 posted -7.74. Turnover was also consistently meaningful, including 15.25 in 2025-06-30, 15.62 in 2024-09-30, and 14.71 in 2023-12-31, which helps explain why modest absolute returns can still translate into weak benchmark-relative results.

Before accepting the baseline, a user should inspect three things: concentration, implementation drag, and which recent changes actually drove returns. Concentration is moderate but meaningful at 17.88% in the top 5 and 32.62% in the top 10. Implementation is not trivial because the backtest cites 3,063 trades and 1.17% total estimated cost, with a reporting-lag replication process. And the latest portfolio changes are substantial enough to matter—new MIDD, CLB, and BOKF plus exits in GNRC, MHK, and GNTX—so the next step is to test whether those trades improved the current sector mix or simply added more cyclical risk.